Baxter uses cell separation technology, enters stem cell field

04/18/2007 | Reuters

Best known for IV drips, Baxter International, has quietly entered the $1 billion potential market of stem cell research with a trial making use of its cell separation technology. The trial uses autologous stem cell therapy, which involves harvesting stem cells from the patient's own bone marrow, to repair oxygen-deprived heart tissue. The drug G-CSF is administered to stimulate the bone marrow to produce more stem cells.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI